Cyanine5 羧酸 (Cyanine5 carboxylic acid)

貨號 數量 價格 交貨時間
13090 1 mg
$110.00
現貨
23090 5 mg
$210.00
現貨
43090 25 mg
$449.90
現貨
53090 50 mg
$769.90
現貨
63090 100 mg
$1190.00
現貨
Found better price? Let us know and we will propose the way forward!
非活化羧酸,Cy5® 游離羧酸的類似物。含有 Cyanine5 螢光團。

該染料的水溶性不好,但可以溶解在水與有機相(DMF、DMSO、醇)的混合液中,以獲得材料的有用濃度。可提供其水溶版。

該分子可被視為非反應性染料,用於對照樣品和儀器校准。對於與胺和蛋白質標記的偶聯,請考慮使用Cyanine5 NHS 酯或水溶性sulfo-Cyanine5 NHS 酯

顧客還購買了這個產品

外观: 深金固體
分子量: 519.12
CAS 编号: 1032678-07-1 (chloride), 195867-59-5 (inner salt), 766503-38-2 (without anion)
分子式: C32H39ClN2O2
IUPAC 名称: 3H-​Indolium, 2-​[5-​[1-​(5-​carboxypentyl)​-​1,​3-​dihydro-​3,​3-​dimethyl-​2H-​indol-​2-​ylidene]​-​1,​3-​pentadien-​1-​yl]​-​1,​3,​3-​trimethyl-​, chloride
溶解度: 溶於有機溶劑(DMF、DMSO、二氯甲烷),極難溶於水(0.25 mM,130 mg/L)
质量控制: NMR 1H, HPLC-MS (95%)
储存条件:
MSDS: 下載
產品規格

激发/吸收极大值,纳米: 646
ε, 摩尔吸光系数,cm⁻¹: 250000
发射极大值,纳米: 662
荧光量子产率: 0.2
CF260: 0.03
CF280: 0.04

產品引用

  1. Tsanaktsidou, E.; Margaroni, M.; Karagouni, E.; Kiparissides, C.; Kammona, O. In Vitro Assessment of a Doubly Adjuvanted Self-Emulsified Nanoemulsion as a Delivery Vehicle for Antigenic Proteins. Pharmaceutics, 2025, 17(7), 870. doi: 10.3390/pharmaceutics17070870
  2. Carreira, B.; Acúrcio, R. C.; Matos, A. I.; Moura, L. I. F.; Afonso, M. B.; Viana, A. S.; Santos, F. M. F.; Gois, P. M. P.; Rodrigues, C. M. P.; Guedes, R. C.; Satchi-Fainaro, R.; Florindo, H. F. Polymeric-Based Neoantigen Nanovaccine Synergizes with PD-1/PD-L1 Modulators, Reprogramming the Melanoma Microenvironment. Journal of Controlled Release, 2025, 387, 114178. doi: 10.1016/j.jconrel.2025.114178
  3. Tchatchiashvilli, T.; Duering, H.; Mueller-Boetticher, L.; Grune, C.; Fischer, D.; Pletz, M.W.; Makarewicz, O. PEG-PLGA nanoparticles deposited in Pseudomonas aeruginosa and Burkolderia cenocepacia. Journal of Pharmaceutical Analysis, 2024, 14(12), 100939. doi: 10.1016/j.jpha.2024.01.007
  4. Mamani, U.-F.; Ibrahim, M. N.; Liu, Y.; Fetse, J.; Lin, C.-Y.; Kandel, S.; Nakhjiri, M.; Koirala, S.; Guo, Y.; Alahmari, M.; Cheng, K. Exploring Multivalency in the Development of Anti-PD-L1 Peptides for Cancer Immunotherapy. Pharmaceutical Research, 2024, 41(12), 2275–2288. doi: 10.1007/s11095-024-03803-1
顯示更多 (31)
已添加您的物品. 查看您的 購物車繼續結賬
物品數量不正確.